NASDAQ · Shell Companies · USD

Drugs Made In America Acquisition Corp. (DMAA) Stock Analysis

Drugs Made In America Acquisition Corp. (DMAA) is a Shell Companies stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DMAA

$10.87

−$0.00 (−0.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DMAA with… →

DMAA Key Statistics

As of Oct 21, 2026

Trading

Open: $10.87
Previous Close: $10.87
Day's Range: 10.86–10.87
52-Week Range: 10.29–10.89
Volume: 7.27K

Valuation

Market Cap: $263.77M
P/E Ratio: 60.36
EPS (ttm): 0.18

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): $5.94M
Shares Outstanding: 24.28M
1-Year Return: +5.49%

Dividend and dates

Avg Volume: 19.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DMAA closed at $10.87, +5.49% over 1 year.

Drugs Made In America Acquisition Corp. (DMAA) has a market capitalization of $263.77M.

DMAA Stock Return by Calendar Year

Drugs Made In America Acquisition Corp. (DMAA) return since Feb 2025: what $10,000 became

1 year: $10,000 $10,549; +5.49%
Since Feb 2025: $10,000 $10,909; +9.09%

If you had invested $10,000 in Drugs Made In America Acquisition Corp. (DMAA) at the close on February 25, 2025, the earliest close on record here, it would have been worth $10,909 at the close on October 21, 2026: +9.09% in total, +5.41% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+4.73%
2025 (partial year)	+4.16%

As of October 21, 2026.

DMAA Valuation vs Shell Companies Median

Median of 309 stocks

Metric	DMAA	Shell Companies median	vs median
P/E	60.36	49.16	23% above

Medians across 309 Shell Companies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

The market values Drugs Made In America Acquisition Corp. (DMAA) at $263.77M. The company sits in the Financial Services sector, in the Shell Companies industry.

Over the past 52 weeks the price has ranged from $10.29 to $10.89. DMAA last closed at $10.87 on October 21, 2026. That is $0.00 (−0.05%) against the previous close. The latest close sits 5.59% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Net income for the same year was $5.94M. Earnings per share on a trailing basis come to 0.18.

Valuation Assessment

On trailing earnings, the shares are priced at 60.36 times earnings. That is 22.8% above the Shell Companies median of 49.16. The medians here are taken across 309 Shell Companies companies that report the metric.

Daily returns over the trailing 1 year annualize to a volatility of 1.87%. Over the trailing twelve months the total return is +5.49%. The stored price history starts on February 25, 2025, and the total return since then is +9.09%.

Growth & Income

No dividend is on file for DMAA.

So far in 2026 the total return is +4.73%.

Peer Comparison

Drugs Made In America Acquisition Corp. (DMAA) operates in the Shell Companies industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Drugs Made In America Acquisition Corp.	DMAA	$263.77M	60.4
Vylor Inc.	VYLR	$49.89B	106.8
Drugs Made In America Acquisition II Corp.	DMII	$649.10M	34.0
Churchill Capital Corp XI	CCXI	$621.61M	—

The Shell Companies industry average P/E ratio is 49.2x. Drugs Made In America Acquisition Corp. trades at a P/E of 60.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Shell Companies Stocks

VYLR

Vylor Inc.

$49.89B

DMII

Drugs Made In America Acquisition II Corp.

$649.10M

CCXI

Churchill Capital Corp XI

$621.61M

EVAC

EQV Ventures Acquisition Corp. II

$603.77M

BCSS

Bain Capital GSS Investment Corp.

$596.26M

CEPF

Cantor Equity Partners IV, Inc.

$587.79M

View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.11T

JPM

JPMorgan Chase & Co.

$890.13B

Visa Inc.

$765.68B

Mastercard Incorporated

$545.42B

BAC

Bank of America Corporation

$358.24B

View all Financial Services stocks →

About Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.